Leading stem cell and exosome therapy research blog by Cell La Vie, Bangkok. Clinical insights, cost breakdowns, and regenerative treatment guides.
Zimislecel (VX-880) is the first stem cell-derived islet therapy to reach the FDA, and the September 2025 NEJM paper showed 12 of 12 patients achieving insulin independence. Here’s what it means for T1D patients in 2026, who qualifies, and what options exist in Thailand now.
Read More »Diabetic wounds that refuse to heal affect hundreds of thousands of Thais. Discover how exosome therapy and MSC treatment are giving patients a real path to recovery.
Read More »Diabetes affects millions across Thailand. Can stem cell therapy help reverse it? Our Bangkok clinic shares real patient outcomes, THB pricing, and what the latest research says about stem cells for diabetes in 2026.
Read More »In a landmark development for stem cell research and diabetes treatment, Vertex Pharmaceuticals has achieved remarkable success with their investigational therapy VX-880 for type 1 diabetes (T1D). This breakthrough, based on longstanding research from Harvard Stem Cell Institute’s Melton Lab, represents one of the first practical applications of embryonic stem cells in treating a major […]
Read More »Bienvenue dans notre article sur la médecine régénératrice avancée. Dans cet article, nous allons explorer les dernières avancées de cette branche de la médecine qui a révolutionné la manière dont nous traitons les maladies et les blessures. Nous allons également examiner comment la médecine régénératrice avancée peut aider à régénérer les tissus endommagés, ainsi qu’à […]
Read More »Scientists are developing a promising approach for treating type 1 diabetes by using stem cells to create insulin-producing cells (called beta cells) that could replace nonfunctional pancreatic cells.
Read More »